Small molecule · developed by Palvella Therapeutics
QTORIN 3.9% Rapamycin Anhydrous Gel is a topical gel containing rapamycin (sirolimus) at 3.9%. It is being studied in microcystic lymphatic malformation, a congenital vascular malformation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06239480 | Phase 3 | Microcystic Lymphatic Malformation | Active not recruiting | PVLA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Microcystic Lymphatic Malformation
Updated Oct 25, 2026. Something wrong or missing? Report it on the PVLA page.
See PVLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PVLA catalysts and pipeline →